Zacks Investment Research on MSN

REGN soars 41% in six months: Is there more upside potential in 2026?

The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...
pharmaphorum

J&J abandons trial of atopic dermatitis drug

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

Delayed MS Decision and Trial Miss Add to Sanofi’s R&D Challenges

Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...